136-150 of 847
The Future of MS Management: Novel Agents and Clinical Approaches
NeuroFrontiersThe Future of MS Management: Novel Agents and Clinical Approaches
Marisa McGinley, DO
MS Relapse vs Pseudo-Relapse After Infection: COVID-19 Shows Divergent Risk Pattern
NeuroFrontiersMS Relapse vs Pseudo-Relapse After Infection: COVID-19 Shows Divergent Risk Pattern
Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings from the MAPLE-MS Pharmacovigilance Program
NeuroFrontiersPregnancy and Infant Outcomes in Multiple Sclerosis: Findings from the MAPLE-MS Pharmacovigilance Program
Reevaluating Natalizumab Dosing in RRMS: Insights from the NOVA Trial
NeuroFrontiersReevaluating Natalizumab Dosing in RRMS: Insights from the NOVA Trial
Recognizing MS: Understanding Symptoms and Avoiding Misdiagnosis
NeuroFrontiersRecognizing MS: Understanding Symptoms and Avoiding Misdiagnosis
Modern MS Care: Navigating Treatment Options for Better Patient Outcomes
NeuroFrontiersModern MS Care: Navigating Treatment Options for Better Patient Outcomes
- advertisement
Epigenetic Immune Signatures in Alzheimer’s: Implications for Diagnosis and Therapy
NeuroFrontiersEpigenetic Immune Signatures in Alzheimer’s: Implications for Diagnosis and Therapy
David Gate, PhD
Understanding MS: Managing Hidden and Overlooked Symptoms
NeuroFrontiersUnderstanding MS: Managing Hidden and Overlooked Symptoms
Marisa McGinley, DO
Advancing MS Care: Evolving Treatments and High-Efficacy Approaches
NeuroFrontiersAdvancing MS Care: Evolving Treatments and High-Efficacy Approaches
Marisa McGinley, DO
Recognizing the Full Spectrum of MS Symptoms: Multidisciplinary Pathways to Better Care
NeuroFrontiersRecognizing the Full Spectrum of MS Symptoms: Multidisciplinary Pathways to Better Care
Marisa McGinley, DO
ASD in Children with SMA Type I: Diagnostic Challenges in a Multifactorial Context
NeuroFrontiersASD in Children with SMA Type I: Diagnostic Challenges in a Multifactorial Context
Safety and Efficacy of Onasemnogene Abeparvovec in Pediatric SMA Across Expanded Weight Cohorts
NeuroFrontiersSafety and Efficacy of Onasemnogene Abeparvovec in Pediatric SMA Across Expanded Weight Cohorts
- advertisement
New-Onset Ketosis-Prone Diabetes in an Adult with Spinal Muscular Atrophy Type III
NeuroFrontiersNew-Onset Ketosis-Prone Diabetes in an Adult with Spinal Muscular Atrophy Type III
Restoring Immune Balance: Low-Dose IL-2 Shows Promise in Alzheimer’s Research
NeuroFrontiersRestoring Immune Balance: Low-Dose IL-2 Shows Promise in Alzheimer’s Research
Early Evidence Supports Videoconference ACT for Dementia Caregivers with Depression
NeuroFrontiersEarly Evidence Supports Videoconference ACT for Dementia Caregivers with Depression